![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/AJANTPHARM.png)
Share the post "AJANTA PHARMA ‘s Q3 2024-25 Latest News: Revenue Rises by 3.71% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 3.71 % in the past year, decrease in net sales/revenue by -3.41 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 123.99 %. Marginal increase in other income during this quarter, up by 56.26%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for AJANTA PHARMA LTD.. Notable increase of 10.88 % in net profit Year to Year, AJANTA PHARMA LTD.’s profitability increased by 7.58 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 11.51 % Year to Year. EPS increased by 7.7 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1105.15 Cr | Rs. 1186.64 Cr | Rs. 1146.13 Cr | -3.41 % | + 3.71 % |
| Expenses | Rs. 791.08 Cr | Rs. 875.47 Cr | Rs. 825.3 Cr | -5.73 % | + 4.33 % |
| Operating Profit | Rs. 314.07 Cr | Rs. 311.17 Cr | Rs. 320.83 Cr | + 3.1 % | + 2.15 % |
| OPM % | 28.42 % | 26.22 % | 27.99 % | + 1.77 % | -0.43 % |
| Other Income | Rs. 13.59 Cr | Rs. 19.48 Cr | Rs. 30.44 Cr | + 56.26 % | + 123.99 % |
| Interest | Rs. 2.49 Cr | Rs. 6.02 Cr | Rs. 7.91 Cr | + 31.4 % | + 217.67 % |
| Depreciation | Rs. 34.26 Cr | Rs. 34.39 Cr | Rs. 35.97 Cr | + 4.59 % | + 4.99 % |
| Profit before tax | Rs. 290.91 Cr | Rs. 290.24 Cr | Rs. 307.39 Cr | + 5.91 % | + 5.66 % |
| Tax % | 27.8 % | 25.41 % | 24.24 % | -1.17 % | -3.56 % |
| Net Profit | Rs. 210.03 Cr | Rs. 216.48 Cr | Rs. 232.88 Cr | + 7.58 % | + 10.88 % |
| EPS in Rs | Rs. 16.67 | Rs. 17.26 | Rs. 18.59 | + 7.71 % | + 11.52 % |
Today, we’re looking at AJANTA PHARMA LTD.’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 3.71 %. However, it did see a marginal slip of -3.41 % from the previous quarter. Expenses decreased slightly by -5.73 % quarter-on-quarter, aligning with the annual rise of 4.33 %. Operating profit, while up 2.15 % compared to last year, faced a quarter-on-quarter increase of 3.1 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.43 %, but an expansion of 1.77 % sequentially. Other income rose by 56.26 % compared to the last quarter, despite an annual growth of 123.99 %. Interest expenses surged remarkably by 31.4 % from the previous quarter, yet the year-over-year increase remains at a moderate 217.67 %. Depreciation costs climbed by 4.59 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 4.99 %. Profit before tax grew annually by 5.66 % but saw an increase from the preceding quarter by 5.91 %.
Tax expenses as a percentage of profits decreased slightly by -3.56 % compared to last year, with a more notable quarter-on-quarter decrease of -1.17 %. Net profit rose by 10.88 % year-on-year but experienced a 7.58 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 11.52 % but a quarterly rise of 7.71 %. In summary, AJANTA PHARMA LTD.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1105.15 Cr | Rs. 1186.64 Cr | Rs. 1146.13 Cr | -3.41 % | + 3.71 % |
| Expenses | Rs. 791.08 Cr | Rs. 875.47 Cr | Rs. 825.3 Cr | -5.73 % | + 4.33 % |
| Operating Profit | Rs. 314.07 Cr | Rs. 311.17 Cr | Rs. 320.83 Cr | + 3.1 % | + 2.15 % |
| Net Profit | Rs. 210.03 Cr | Rs. 216.48 Cr | Rs. 232.88 Cr | + 7.58 % | + 10.88 % |
| EPS in Rs | Rs. 16.67 | Rs. 17.26 | Rs. 18.59 | + 7.71 % | + 11.52 % |
In reviewing AJANTA PHARMA LTD.’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 3.71 % year-on-year growth, although there was a slight dip of -3.41 % from the previous quarter. Expenses rose by 4.33 % compared to the previous year, with a decrease of -5.73 % quarter-on-quarter. Operating Profit surged by 2.15 % annually, and saw a 3.1 % increase from the last quarter.
Net Profit showed yearly increase of 10.88 %, and experienced a 7.58 % increase from the previous quarter. Earnings Per Share (EPS) rose by 11.52 % annually, however rose by 7.71 % compared to the last quarter. In essence, while AJANTA PHARMA LTD. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/POLYCHEM.png)
